Literature DB >> 25185856

A case of autoimmune urticaria accompanying autoimmune polyglandular syndrome type III associated with Hashimoto's disease, type 1 diabetes mellitus, and vitiligo.

Jacek Kasznicki1, Józef Drzewoski.   

Abstract

We present a case of autoimmune polyglandular syndrome type III (APS III) associated with Hashimoto's disease, type 1 diabetes mellitus, vitiligo and autoimmune urticaria. This rare genetic disorder occurs with unknown frequency in the Polish population. It is characterised by endocrine tissue destruction resulting in the malfunction of multiple organs.Several cases of APS III associated with organ-specific autoimmune diseases such as coeliac disease, hypogonadism and myasthenia gravis, as well as organ-nonspecific or systemic autoimmune diseases such as sarcoidosis, Sjögren syndrome, and rheumatoid arthritis have been described. To the best of our knowledge, we here describe the first case of APS III associated with autoimmune thyroiditis, type 1 diabetes mellitus, vitiligo and autoimmune urticaria in an adult patient.

Entities:  

Mesh:

Year:  2014        PMID: 25185856     DOI: 10.5603/EP.2014.0044

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  3 in total

1.  Metabolic-targeted Combination Therapy With Dichloroacetate and Metformin Suppresses Glioblastoma Cell Line Growth In Vitro and In Vivo.

Authors:  Laura Korsakova; Jan Aleksander Krasko; Edgaras Stankevicius
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Decreased Circulating T Regulatory Cells in Egyptian Patients with Nonsegmental Vitiligo: Correlation with Disease Activity.

Authors:  Doaa Salah Hegab; Mohamed Attia Saad Attia
Journal:  Dermatol Res Pract       Date:  2015-12-15

Review 3.  Autoimmune polyglandular syndrome type III associated with antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis: A case report and literature review.

Authors:  Shiyuan Tian; Baofeng Xu; Ziwei Liu; Rui Liu
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.